Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rao, S.
Right arrow Articles by Cunningham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rao, S.
Right arrow Articles by Cunningham, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1165-1168, 2002
© 2002 European Society for Medical Oncology

Editorial

Advanced pancreatic cancer—5 years on

S. Rao and D. Cunningham*

GI Unit, London and Surrey, Royal Marsden Hospital, UK (E-mail: dcunn@icr.ac.uk)

The first 10% of the full text of this article appears below.

Some 5 years ago we reviewed the literature on the treatment of advanced and metastatic pancreatic cancer. At that time gemcitabine had recently emerged as the new standard treatment for advanced disease based on a relatively small North American randomised trial, which compared gemcitabine to 5-fluorouracil (5-FU) given by bolus injection. Gemcitabine produced superior response rate, survival and clinical benefit [1], and rapidly gained widespread use in North America, but the uptake in Europe was slower—the trial had been criticised for the suboptimal schedule of 5-FU. However, the agent gradually gained clinical acceptance in Europe and with the publication of the National Institute of Clinical Excellence (NICE) guidelines supporting gemcitabine in June 2001, the UK followed suit. Moreover, during these 5 years . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Wagner, P Buechner-Steudel, A Wein, H Schmalenberg, U Lindig, M Moehler, R Behrens, G Kleber, O Kuss, and W. Fleig
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Ann. Onc., January 1, 2007; 18(1): 82 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Oettle, D. Richards, R. K. Ramanathan, J. L. van Laethem, M. Peeters, M. Fuchs, A. Zimmermann, W. John, D. Von Hoff, M. Arning, et al.
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
Ann. Onc., October 1, 2005; 16(10): 1639 - 1645.
[Abstract] [Full Text] [PDF]